Clinical Trials
63 trialsAT02-001
Attralus, Inc.
A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma
Shanghai Simnova Biotechnology Co.,Ltd.
CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma
Sichuan University
Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.
Oncotherapeutics
VICTORY
Melbourne Health
A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis
University of Tennessee Graduate School of Medicine
Double Filtration Plasmapheresis Combined With Chemotherapy
Zhongnan Hospital
A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma
Chongqing Precision Biotech Co., Ltd
Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM
Peking University People's Hospital
AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma
Zhejiang University
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
Celularity Incorporated
Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma
Second Affiliated Hospital, School of Medicine, Zhejiang University
A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd.
Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma
Sorrento Therapeutics, Inc.
Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002#
Tongji Hospital
Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients
Gadeta B.V.
Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
Jiangsu HengRui Medicine Co., Ltd.
Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma
Shanghai Changzheng Hospital
A Study of CAR-T Cells Targeting Both BCMA and GPRC5D in Treatment of Relapsed or Refractory Multiple Myeloma
Zhejiang University
Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma
Keymed Biosciences Co.Ltd
A Single-center Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a BCMA-targeted Universal LCAR-BCX Cells in Patients With Relapsed/Refractory Multiple Myeloma
Shanghai Changzheng Hospital
Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma
Shandong New Time Pharmaceutical Co., LTD
Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma
Hrain Biotechnology Co., Ltd.
Clinical Study of Autologous Natural Killer Cells in Multiple Myeloma
Karolinska University Hospital
Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma
First Affiliated Hospital of Zhejiang University
Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma
Peking Union Medical College Hospital
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
Beijing Immunochina Medical Science & Technology Co., Ltd.
Clinical Study to Evaluate the Safety and Feasibility of spCART-269 Injection in the Treatment of MM
Shanghai Tongji Hospital, Tongji University School of Medicine
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
Peking Union Medical College Hospital
CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma
Chong Kun Dang Pharmaceutical
CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma
Chong Kun Dang Pharmaceutical
MUKeleven
University of Leeds
Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma
The First Affiliated Hospital of Nanchang University
ToTem
University College, London
Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients
Shanghai Theorion Pharmaceutical Co Ltd.
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
The First Affiliated Hospital with Nanjing Medical University
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
Hebei Yanda Ludaopei Hospital
BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma
Second Affiliated Hospital of Xi'an Jiaotong University
LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma
Second Affiliated Hospital of Xi'an Jiaotong University
Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma
Shenzhen Second People's Hospital
BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma
Henan Cancer Hospital
CyBorD-Dara
National University of Ireland, Galway, Ireland